Literature DB >> 16100087

Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Shandra Bipat1, Maarten S van Leeuwen, Emile F I Comans, Milan E J Pijl, Patrick M M Bossuyt, Aeilko H Zwinderman, Jaap Stoker.   

Abstract

PURPOSE: To perform a meta-analysis to obtain sensitivity estimates of computed tomography (CT), magnetic resonance (MR) imaging, and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for detection of colorectal liver metastases on per-patient and per-lesion bases.
MATERIALS AND METHODS: MEDLINE, EMBASE, Web of Science, and CANCERLIT databases and Cochrane Database of Systematic Reviews were searched for relevant original articles published from January 1990 to December 2003. Criteria for inclusion of articles were as follows: Articles were reported in the English, German, or French language; CT, MR imaging, or FDG PET was performed to identify and characterize colorectal liver metastases; histopathologic analysis (surgery, biopsy, or autopsy), intraoperative observation (manual palpatation, intraoperative ultrasonography [US]), and/or follow-up US was the reference standard; and data were sufficient for calculation of true-positive or false-negative values. A random-effects linear regression model was used to obtain sensitivity estimates in assessment of liver metastases.
RESULTS: Of 165 identified relevant articles, 61 fulfilled all inclusion criteria. Sensitivity estimates on a per-patient basis for nonhelical CT, helical CT, 1.5-T MR imaging, and FDG PET were 60.2%, 64.7%, 75.8%, and 94.6%, respectively; FDG PET was the most accurate modality. On a per-lesion basis, sensitivity estimates for nonhelical CT, helical CT, 1.0-T MR imaging, 1.5-T MR imaging, and FDG PET were 52.3%, 63.8%, 66.1%, 64.4%, and 75.9%, respectively; nonhelical CT had lowest sensitivity. Estimates of gadolinium-enhanced MR imaging and superparamagnetic iron oxide (SPIO)-enhanced MR imaging were significantly better, compared with nonenhanced MR imaging (P = .019 and P < .001, respectively) and with helical CT with 45 g of iodine or less (P = .02 and P < .001, respectively). For lesions of 1 cm or larger, SPIO-enhanced MR imaging was the most accurate modality (P < .001).
CONCLUSION: FDG PET had significantly higher sensitivity on a per-patient basis, compared with that of the other modalities, but not on a per-lesion basis. Sensitivity estimates for MR imaging with contrast agent were significantly superior to those for helical CT with 45 g of iodine or less. RSNA, 2005

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100087     DOI: 10.1148/radiol.2371042060

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  122 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Current treatment for colorectal liver metastases.

Authors:  Evangelos P Misiakos; Nikolaos P Karidis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

3.  The role of 18FDG PET/CT in the management of colorectal liver metastases.

Authors:  Alec H Engledow; James R A Skipworth; Farrokh Pakzad; Charles Imber; Peter J Ell; Ashley M Groves
Journal:  HPB (Oxford)       Date:  2011-11-14       Impact factor: 3.647

4.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

5.  Surgical management of colorectal liver metastases.

Authors:  Waleed M Mohammad; Fady K Balaa
Journal:  Clin Colon Rectal Surg       Date:  2009-11

6.  Guidelines for resection of colorectal cancer liver metastases.

Authors:  O J Garden; M Rees; G J Poston; D Mirza; M Saunders; J Ledermann; J N Primrose; R W Parks
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 7.  Microbubble ultrasound contrast agents: an update.

Authors:  Emilio Quaia
Journal:  Eur Radiol       Date:  2007-03-10       Impact factor: 5.315

8.  Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases?

Authors:  Ludwig G Strauss; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

9.  Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?

Authors:  Michael Mantatzis; Stylianos Kakolyris; Kyriakos Amarantidis; Anastasios Karayiannakis; Panos Prassopoulos
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

10.  The impact of 18F-FDG PET/CT in patients with liver metastases.

Authors:  Siew C Chua; Ashley M Groves; Irfan Kayani; Leon Menezes; Svetislav Gacinovic; Yong Du; Jamshed B Bomanji; Peter J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.